English Adalimumab Tender Marks Progress, But Is Not Perfect
An English adalimumab tender in effect from 1 December last year aided industry sustainability by awarding deals to multiple biosimilar suppliers. But there is still room for improvement, the BBA’s Warwick Smith believes.
You may also be interested in...
The UK is putting itself in a position to play a leading role in global biosimilars regulation, thanks to a proposed new registration pathway that will not require comparative efficacy data, delegates to a Westminster Health Forum online conference heard earlier today.
As Warwick Smith steps down after 25 years as leader of the British Generic Manufacturers Association, he talks about how far the country’s off-patent industry has come over the last quarter-century – including the acceptance of generics, the advent of biosimilars, and how freedom of pricing has helped to keep costs low while maintaining sustainable pricing – in the first part of an exclusive interview with Generics Bulletin.
An ASBM survey of 575 biologic prescribers in six western European countries has found that 90% of physicians are familiar with biosimilars, compared to 76% in 2013. The results were presented and discussed at the 2019 ESMO Congress.